AU2003245700A1 - Pyrazolopyridine derivatives - Google Patents

Pyrazolopyridine derivatives

Info

Publication number
AU2003245700A1
AU2003245700A1 AU2003245700A AU2003245700A AU2003245700A1 AU 2003245700 A1 AU2003245700 A1 AU 2003245700A1 AU 2003245700 A AU2003245700 A AU 2003245700A AU 2003245700 A AU2003245700 A AU 2003245700A AU 2003245700 A1 AU2003245700 A1 AU 2003245700A1
Authority
AU
Australia
Prior art keywords
pyrazolopyridine derivatives
pyrazolopyridine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003245700A
Inventor
Jason Witherington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203295A external-priority patent/GB0203295D0/en
Priority claimed from GB0206610A external-priority patent/GB0206610D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2003245700A1 publication Critical patent/AU2003245700A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003245700A 2002-02-12 2003-02-12 Pyrazolopyridine derivatives Abandoned AU2003245700A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0203295.1 2002-02-12
GB0203295A GB0203295D0 (en) 2002-02-12 2002-02-12 Novel method and compounds
GB0206610.8 2002-03-20
GB0206610A GB0206610D0 (en) 2002-03-20 2002-03-20 Novel compounds
PCT/GB2003/000576 WO2003068773A1 (en) 2002-02-12 2003-02-12 Pyrazolopyridine derivatives

Publications (1)

Publication Number Publication Date
AU2003245700A1 true AU2003245700A1 (en) 2003-09-04

Family

ID=27736199

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003245700A Abandoned AU2003245700A1 (en) 2002-02-12 2003-02-12 Pyrazolopyridine derivatives

Country Status (2)

Country Link
AU (1) AU2003245700A1 (en)
WO (1) WO2003068773A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112313232A (en) * 2018-05-02 2021-02-02 Jw中外制药公司 Novel heterocyclic derivatives

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582630B2 (en) * 2002-10-15 2009-09-01 Smithkline Beecham Corporation Pyradazine compounds as GSK-3 inhibitors
CL2004000398A1 (en) * 2003-02-27 2005-03-18 Uriach Y Compania S A J COMPOUNDS DERIVED FROM PIRAZOLOPIRIDINAS, ITS SALTS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT DISEASES MEDIATED BY P38 KINASES, ESPECIALLY BY CITOCINES, TNF-ALFA, IL-1, IL-6 AND / OR IL-8, SUCH AS DISEASE
ES2214976B1 (en) * 2003-03-14 2005-12-16 J. URIACH & CIA S.A. "NEW DERIVATIVES OF PIRAZOLOPIRIDINAS".
ES2214150B1 (en) * 2003-02-27 2005-12-01 J. URIACH & CIA S.A. "NEW DERIVATIVES OF PIRAZOLOPIRIDINAS".
DE102004005172A1 (en) * 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazole derivatives as inhibitors of the hormone sensitive lipase
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
ES2241496B1 (en) * 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRIDINA.
AU2005269387A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
EP2264033A1 (en) 2004-07-27 2010-12-22 SGX Pharmaceuticals, Inc. 3,5-DIPHENYL-SUBSTITUTED PYRROLO[2,3b]PYRIDINES USEFUL AS KINASE INHIBITORS
AR050188A1 (en) * 2004-08-03 2006-10-04 Uriach Y Compania S A J CONDENSED HETEROCICLIC COMPOUNDS USED IN THERAPY AS INHIBITORS OF P38 KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PL1789390T3 (en) 2004-09-02 2012-04-30 Genentech Inc Pyridyl inhibitors of hedgehog signalling
DE602006005242D1 (en) 2005-06-27 2009-04-02 Sanofi Aventis PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF KINASE 1 OF THE BETA ADRENEER RECEPTOR
ES2270715B1 (en) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. NEW DERIVATIVES OF PIRAZINA.
FR2889526B1 (en) * 2005-08-04 2012-02-17 Aventis Pharma Sa SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
ES2274712B1 (en) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. NEW IMIDAZOPIRIDINE DERIVATIVES.
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP2009523748A (en) * 2006-01-18 2009-06-25 シエナ ビオテク ソシエタ ペル アチオニ Modulators of α7 nicotinic acetylcholine receptors and their use in therapy
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP1870410A1 (en) * 2006-06-13 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ES2303776B1 (en) * 2006-12-29 2009-08-07 Laboratorios Almirall S.A. DERIVATIVES OF 5-PHENYL-6-PIRIDIN-4-IL-1,3-DIHIDRO-2H-IMIDAZO (4,5-B) PIRIDIN-2-ONA USEFUL AS ANTAGONISTS OF ADENOSINE A2B RECEIVER.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008282156B2 (en) * 2007-07-31 2014-07-17 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
WO2009058298A1 (en) * 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3, receptor antagonists for treatment of pain
EP2070929A1 (en) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
PE20131210A1 (en) 2007-12-19 2013-10-31 Genentech Inc 5-ANILINOIMIDAZOPYRIDINE DERIVATIVES AS MEK INHIBITORS
AU2009222144A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Pyrazole [3, 4-b] pyridine Raf inhibitors
CL2009000447A1 (en) 2008-02-29 2010-01-04 Array Biopharma Inc Y Genentech Inc Compounds derived from (1h-pyrrolo {2,3-b} pyridin-5-yl) -sulfonamido-substituted benzamide; preparation procedure; pharmaceutical composition; and its use in the treatment of cancer, through the inhibition of raf.
WO2010016846A1 (en) * 2008-08-08 2010-02-11 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
WO2010027114A1 (en) * 2008-09-05 2010-03-11 Choongwae Pharma Corporation Use of pyrazole-pyridine derivatives and its salts for treating or reventin osteoporosis
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011025968A1 (en) 2009-08-28 2011-03-03 Array Biopharma Inc. 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase
FR2951172B1 (en) * 2009-10-13 2014-09-26 Pf Medicament PYRAZOLOPYRIDINE DERIVATIVES AS ANTI-CANCER AGENT
WO2011049988A2 (en) * 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Indazoles to treat flaviviridae virus infection
US8487102B2 (en) * 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR20120063283A (en) * 2010-12-07 2012-06-15 제일약품주식회사 Novel pyrazolopyridine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
FR2970967B1 (en) * 2011-01-27 2013-02-15 Pf Medicament AZAINDAZOLE OR DIAZAINDAZOLE DERIVATIVES AS A MEDICINAL PRODUCT
SI2797888T1 (en) 2011-12-31 2017-01-31 BeiGene, Ltd. Mourant Ozannes Corporate Services (Cayman) Limited Fused tricyclic compounds as raf kinase inhibitors
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
JP6380862B2 (en) 2013-06-28 2018-08-29 ベイジーン リミテッド Condensed tricyclic amide compounds as inhibitors of multiple kinases
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
KR102022866B1 (en) * 2014-08-19 2019-09-19 상하이 하이헤 파마수티컬 컴퍼니 리미티드 Indazole compounds as fgfr kinase inhibitor, preparation and use thereof
CN106279119B (en) * 2015-05-27 2020-06-16 上海海和药物研究开发有限公司 Preparation and application of novel kinase inhibitor
KR101753654B1 (en) 2015-10-21 2017-07-05 한국화학연구원 Novel 3-(4-(piperazin-1-yl)benzamido)-1H-pyrazolopyridine derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for use in preventing or treating MELK(maternal embryonic leucine zipper kinase) activity related diseases containing the same as an active ingredient
CN112823036A (en) * 2018-07-03 2021-05-18 艾福姆德尤股份有限公司 Compounds and compositions for treating diseases associated with STING activity
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
US11773121B2 (en) * 2020-01-30 2023-10-03 Virovax Llc Antiviral compounds
CN111303118B (en) * 2020-02-17 2021-11-09 清华大学 Compounds and their use in the treatment of hepatitis B
KR102580387B1 (en) * 2021-05-07 2023-09-19 한국화학연구원 Pharmaceutical compositions comprising novel pyrazolo[3,4-b]pyridine derivatives for preventing or treating metabolic diseases including obesity and diabetes mellitus, or nonalcholic steatohepatitis
PE20240931A1 (en) * 2021-08-10 2024-04-30 Ifm Due Inc COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4878601A (en) * 2000-04-20 2001-11-07 Mitsubishi Corporation Aromatic amide compounds
EP1319001A1 (en) * 2000-09-22 2003-06-18 Smithkline Beecham Plc Pyrazolopyridines and pyrazolopyridazines as antidiabetics
US7105532B2 (en) * 2000-12-19 2006-09-12 Smithkline Beecham Corporation Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors
EP1435957B1 (en) * 2001-04-30 2009-06-17 Vertex Pharmaceuticals Incorporated Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112313232A (en) * 2018-05-02 2021-02-02 Jw中外制药公司 Novel heterocyclic derivatives
CN112313232B (en) * 2018-05-02 2024-03-08 Jw中外制药公司 Novel heterocyclic derivatives

Also Published As

Publication number Publication date
WO2003068773A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
AU2003245700A1 (en) Pyrazolopyridine derivatives
AU2003248588A1 (en) Substituted pyrrolopyridines
AU2002352142A1 (en) Pyrazolopyridine derivatives
EP1682493B8 (en) Amidoacetonitrile derivatives
AU2003275266A1 (en) Therapeutic compounds based on pyrazolopyridine derivatives
IL196021A0 (en) Pyrazolopyridine derivatives uses
AU2003301424A1 (en) Perfluoropolyether derivatives
AU2003273865A1 (en) Amino-propanol derivatives
AU2003211362A1 (en) N-hydroxycarboxamide derivative
EP1606277B8 (en) Imidazol-4-yl-ethynyl-pyridine derivatives
AU2003227712A1 (en) Tetrahydroisoquinoline derivatives
AU2003301968A1 (en) 4-aminomethyl-1-aryl-cyclohexylamine derivatives
AU2003235123A1 (en) Unit
AU2003226487A1 (en) Formulation
AU2003213185A1 (en) Arylsulfone derivatives
AU2003273885A1 (en) Morpholine-bridged indazole derivatives
AU2003278369A1 (en) 3-cyano-quinoline derivatives
AU2003296564A1 (en) 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives
AU2003215676A1 (en) Pyrazolopyrimidines derivatives
EP1706373B8 (en) Amidoacetonitrile derivatives
AU2003222659A1 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
AU2003234131A1 (en) 5-o-mycaminosyltylonide derivatives
AU2003290216A1 (en) Porphyrin derivatives
AU2003281366A1 (en) 1-aralkyl-n-(3-quinolyl)-1-cyclohexanecarboxamide derivative
AU2003206730A1 (en) Fitting

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase